Showing posts with label A54(2). Show all posts
Showing posts with label A54(2). Show all posts

13 August 2026

T 0964/24 - Inventive polymorphs

Key points

  •  This decision deals with novelty, namely a "counting to two" case, and inventive step of polymorphs.
  • Claim 1 of the main request is directed to the citrate salt of the compound SCY-078. Novelty over D6 is at issue.
  • The Board: "As set out above, claim 49 of D6 relates both to SCY-078 in its free-base form and to a pharmaceutically acceptable salt thereof. Furthermore, the passage quoted above [column 21, line 54 to column 22, line 21]  discloses citrate as a pharmaceutically acceptable salt. The board acknowledges that this disclosure is not made specifically in the context of SCY-078, but rather in relation to all the compounds of the invention of D6. However, since SCY-078 is one of those compounds, the skilled person would already derive directly and unambiguously from this disclosure that citrate also applies to SCY-078. "
  • The passage is a list of pharmaceutically acceptable salts and includes citrate.
  • Hence, citrate is one selection; a question is whether claim 49 / SCY-078 is a second selection, or at least the embodiment "pharmaceutically acceptable salt" of claim 49. 
  • "even if one were to accept the respondent's [proprietor's] rather formal approach that, in addition to selecting citrate from the passage quoted above, a pharmaceutically acceptable salt of SCY-078 must be selected from claim 49 instead of the free base of SCY-078, D6 provides a clear technical link between these selections. Accordingly, D6 directly and unambiguously discloses SCY-078 citrate as defined in claim 1 of the main request."
  • Claim 1 of the AR recites 10 crystalline forms of the citrate salts, each defined by an XRD pattern. Inventive step is at issue.
  • "At the oral proceedings, the appellant [opponent] considered, inter alia, D6 as possible closest prior art. [The opponent] stated that it regarded the pharmaceutically acceptable salt of SCY-078 disclosed in claim 49 as the starting point for assessing inventive step. However, it did not start from the citrate of SCY-078 as disclosed in D6 (see assessment of main request above). To the benefit of the appellant [opponent] [*], it is assumed in the following that this is correct."
    • *  see below, the selection of "citrate" is considered as the distinguishing feature that provides for inventive step. How this is to be reconciled with the Board's conclusion of lack of novelty of that feature in connection with the Main Request, and with Article 114(1) EPC in that respect, is not entirely clear to me.
  • "table 18 of the application as filed shows that the Type A citrate crystal form exhibits superior kinetic solubility in fasted state simulated intestinal fluid (FaSSIF) and in fed state simulated intestinal fluid (FeSSIF) compared with other salts of SCY-078 (hippurate, fumarate, mesylate, phosphate). "
  • "none of the documents in the proceedings teaches the use of citrate in order to increase bioavailability of a drug relative to other salt-forming options."
  • The claims are held to be inventive. 
EPO 
The link to the decision is provided after the jump.

15 June 2026

T 0443/24 - Different term, same thing, not novel

Key points

  • " whether D9 anticipates that the aortic section has "diamond-shaped cells" depends on how this term is interpreted. As set out in the Order of G 1/24, the description and drawings shall always be consulted to interpret the claims when assessing the patentability of an invention. 
  • "The contested patent neither defines a diamond shape nor explicitly states what is meant by "diamond-shaped cells". However, it refers to cells that are essentially identical in shape to those in the top row of cells in Figure 1 of D9 as "diamond-shaped cells" (see, for example, the cells in Figure 1 of the contested patent and the corresponding description in column 3, lines 41 to 43; compare with the shape of the cells in the top row in Figure 1 of D9). Accordingly, the term "diamond-shaped cells" in feature 1.4 of the contested patent is construed as encompassing cells such as the cells of the top row of cells in Figure 1 of D9. 
  • "This conclusion is not altered by the fact that D9 uses the term "onion-shaped cell structure" (page 20, line 12) rather than "diamond-shaped cells" to describe the shape, as anticipation does not require the same literal term to be explicitly disclosed."

EPO 
The link to the decision is provided after the jump.

20 May 2026

T 0953/23 - The proprietor's own prior use

Key points

  • The inventor is "PREISSMAN, Howard".  The OD rejected the opposition. The opponent appeals. The proprietor is Keller Medical, Inc.
  • "D1 is an article published in 2012, i.e. after the filing date of 29 April 2009 of the patent [filed without priority]. The article concerns the development of the "Keller Funnel". 
  • "In the section of D1 entitled "Serendipity", second paragraph, it is explained that Mr Preissman perfected the funnel's design  ..."
  • "On the first page of the article (p. 283 at the bottom right), it is stated that "[w]e began introducing the prototype and its potential benefits to influential plastic surgeons at the beginning of 2009 ...". The appellant [opponent] alleged that it followed from this passage that the invention had been disclosed to the public, namely to influential plastic surgeons, before the filing date of the patent in suit."
  • The Board: "In the absence of any indication of a different understanding, the Board interprets the expression "at the beginning of 2009" in accordance with general linguistic usage. According to which "at the beginning of 2009" refers to a point of time not later than within the first three months of 2009. Had a later period been intended, wording such as mid 2009 would have been used. Thus, the Board is convinced that, on the balance of probabilities, the disclosure to the influential plastic surgeons did take place before the filing date of the patent in suit."
  • The Board, earlier in the decision: "it is common ground that the facts relating to the prior use were not under the control of the appellant and that both parties had equal access to the evidence. In accordance with the principle of free evaluation of evidence and in line with the established case law (see CLBA 11th edition, III.G.4.3.2 a)), the Board assessed the relevant facts on the basis of the balance of probabilities."
    • I'm not sure if the part in italics is entirely accurate, but for the outcome of the case, this detail does not matter.
  • The patent is revoked.
EPO 
The link to the decision is provided after the jump.

22 January 2026

T 0143/24 - (II) Sold product as prior art

Key points

  • For some reason, I've found a second post about this decision in my stock. This second post has a slightly different angle. I decided to publish it as well. 
  • The opponent alleges a public prior use, based on the sale of a polymer. The polymer sold was not reproducible.
  • The Board, in translation: "If prior public use is claimed to be the sale of an item and its delivery to a customer, the recognizable features of the item sold generally become publicly accessible if the item is transferred without a confidentiality agreement and can be analyzed by a person skilled in the art. Contrary to the patent proprietor's view, reproducibility is not necessary for a product that is freely accessible and analyzable on the market to be considered prior art under Article 54(2) EPC (G 1/23, Reasons 73, 74)."
    • As a comment, I think that for novelty, the product is prior art for all its properties, even those that cannot be measured. If you invent a new device that is able to measure a newly-developed property and carry out the measurements on known materials (say, water, graphene), a claim defining that material in terms of the new property is not novel, in my view. The exception for second medical use claims (drafted as product claims under EPC2000) in fact confirms the rule. 
  •  "However, free access on the market is lacking if the product is sold subject to confidentiality agreements. "
    • I think we have to be precise about what we mean by 'confidentiality'. Linguistically, confidentiality refers to information, and a physical product is not information. Do we mean a non-analysis clause? A clause that the sold product (e.g., apparatus) may not leave the premises of the buyer? Should the sold apparatus be hidden from visitors' view? 
  • In this case, the documents submitted by the opponent regarding the sale indicate that the general terms and conditions of the seller applied. The opponent was the seller. 
  • The Board: "In the present case, the opponent has neither submitted the terms and conditions mentioned in the contract documents it has provided, nor has it presented specific details regarding their concrete content or individual agreements relating to the respective sales. In such a case, the opponent cannot generally evade its burden of proof by merely asserting in general terms that no confidentiality agreement was concluded between the contracting parties. It is also not possible to deny the opposing party's statements on this matter with mere lack of knowledge, as this would only be permissible if the patent holder were subject to the burden of proof."
  • "Confidentiality agreements are frequently included in so-called "General Terms and Conditions," the content of which is not individually negotiated for each legal transaction but pre-formulated for an indefinite number of cases. At least when the public accessibility of a product is based on a sales transaction which—as in this case—was based on general terms and conditions, according to the appellant's submissions and the documents presented, the appellant [opponent ] must therefore generally also present information on the content of these general terms and conditions in order to meet its burden of proof."
  • The proprietor had submitted the general terms and conditions of the same seller (from a different transaction). These read as follows: "12. - Confidentiality - All technical, commercial, economic, or other information or data relating to the supplier's business, including but not limited to its formulas, product specifications, services, plans, programs, processes, products, costs, operations, and customers, which the buyer, its affiliates, officers, or employees become aware of in the performance of the contract, shall be treated as the supplier's confidential property, and the buyer is obligated not to use such information or data unless it benefits the supplier in the performance of the contract, and the buyer may only use such information or data for the benefit of the supplier in the performance of the contract." 
    • It may require careful analysis to determine whether this clause prohibits the buyer from analysing the product after the buyer has paid and performed under the contract.
    • More generally, I wonder if the Board's focus on confidentiality is consistent with G 1/23. If the seller is willing to sell the product to anybody upon payment of the price and (tacit) acceptance of the general terms and conditions, can the seller then later patent the product (cf. G 1/23, r.75)

EPO 
The link to the decision is provided after the jump.

14 November 2025

T 0807/23 - Applying G 1/23

Key points

  • Perhaps unsurprisingly, a case about polymers.
  • "In the decision under appeal, the opposition division found that the data provided in D11 did not enable the skilled person to prepare the commercial product Borclear RB709CF disclosed in that document. Therefore, in view of G 0001/92 and T 1833/14, it was concluded that D11 was not state of the art within the meaning of Article 54(2) EPC (contested decision, page 12, first to fifth paragraph)."
    • The decision of the OD was taken on 14.02.2023. The referral in case G 1/23 was in June 2023.
  •   "In application of [G 1/23], it is clear to the present Board that the reproducibility requirement is no longer a valid criterion to assess whether a product put on the market before the date of filing of the opposed patent or technical information about such a product is state of the art within the meaning of Article 54(2) EPC. This was also not disputed by the parties during the oral proceedings.

    1.4 Accordingly, the product Borclear RB709CF and the corresponding data sheet D11 are state of the art within the meaning of Article 54(2) EPC."

  • The proprietor/respondent raised the question of whether document D11 could be taken as the closest prior art. The Board does not make a decision on this question. 

  •  Decision G 0001/23 sets out further considerations regarding the use of non-reproducible prior art in relation to inventive step (see in particular points 92, 93, 95 and 96 of the reasons). As these considerations were not available to the parties and the opposition division at the time of the decision under appeal, the case should also be remitted to the opposition division so that it can consider whether D11 is suitable to be taken as the closest prior art in light of G 0001/23 after giving both parties the possibility to take position on the application of the decision of the Enlarged Board to the present case."

  • Point 96 of G 1/23: 96. "It follows from the above that disclosed but non-reproducible features of a product may, but need not, flow into the assessment of inventive step. Adding some lemon juice to a glass of Coca-Cola for a less sweet taste may not be inventive simply because the recipe for Coca-Cola is secret and therefore the original taste of Coca-Cola is considered as unattainable. On the other hand, achieving the original taste of Coca-Cola without sugar or caffeine is probably an unsolved problem at the time of writing. There are no formal and strict rules as to how a non-reproducible but publicly available product or any of its properties can be taken into account when inventive step is examined. The relevant technical teaching that a skilled person would take from such a product is always case specific - it depends on both the product in question and the invention under examination."
    • As to the first example, would the claim under examination be: "a composition comprising Coca-Cola and lemon juice"? Would that claim be clear? If not, would the claim be " a composition comprising ... [ the secret ingredients of Coca Cola] + lemon juice"?   Is it correct that the EBA stipulates that such a claim would not be inventive, even if the recipe in square brackets was non-obvious? Would it make a difference if the claim were rewritten into a claim for the preparation method?

 

 
  • It seems predictable that the Board will have to decide on the question in a second appeal. 


EPO 
The link to the decision can be found after the jump.

27 October 2025

T 1408/23 - A commercially available polymer

Key points

  • "In Example 1 of D1 [the closest prior art], the [pressure-sensitive adhesive (PSA)]  polymer in layer 3 is a polyisobutylene (PIB) and the PSA polymer in intermediate layer 2 is Duro-Tak 87-2852 (paragraphs [0108] and [0109]). The parties did not dispute that Duro-Tak 87-2852 was a well-known and commercially available crosslinked polyacrylate generally used in TTS. This was confirmed by D12, which discloses a selection of commercially available PSA polymers for use in TTS."
    • G 1/23 is not mentioned, but this reasoning is consistent with it. G 1/23 was issued a couple of weeks before the (oral) decision in the present case.

  • On the objective technical problem
    "
     the examples in the patent show that a TTS in accordance with claim 1 retains its adhesive properties during storage. This technical effect has not been compared with the TTS of the closest prior art, but there is no reason to believe that the TTS of claim 1 is superior to or substantially different from the one in Example 1 of D1: as stated in paragraph [0090] of the patent, the maintenance of the adhesive strength during storage is attributed to the fact that the TTS has two PSA layers, a feature that is also present in the TTS of the closest prior art. Consequently, it cannot be concluded that the distinguishing features produce any technical effect over the TTS of the closest prior art."
  •  "In the absence of a technical effect over the closest prior art, the objective technical problem has to be defined as the provision of an alternative TTS."
  • "The respondent [proprietor] argued that, even if no technical effect has been demonstrated in comparison with the closest prior art, the technical effect shown in the patent has to be considered in the definition of the objective technical problem."
  • "In the Board's view, the technical effect shown in the patent is implicitly considered when the objective technical problem is defined as an alternative. As set out above (point 1.4), it can be expected that the TTS in Example 1 of D1 also maintains its adhesive strength during a certain period of storage. This seems reasonable on its own, given that TTS are not prepared in situ and must retain their adhesive strength for at least a period extending from preparation to commercialisation and application by the final user. Thus, whether the objective technical problem is defined as an alternative or as an alternative which maintains adhesive strength during a period of storage does not change the situation."

  • Commerical products as combination prior art
  • "Considering that the essential function of PIB in Example 1 of D1 is to provide good adhesion to skin, the skilled person looking for an alternative would turn to the common PSA polymers used in TTS and select in the first place those providing the highest adhesiveness. Such PSA polymers are disclosed in D12 and, in line with the alternative proposed in paragraph [0097] of D1, are all polyacrylates with the exception of Duro-Tak 87-6908, which is a PIB (last entry of the table in D12). In D12, the most adhesive polymers appear to be non-crosslinked polyacrylates, Duro-Tak 87-2051 clearly being the product with the highest adhesiveness. Therefore, in the light of the teaching in D1 and D12, the skilled person would replace the PIB in Example 1 of D1 with Duro-Tak 87-2051. This appears also to be the non-crosslinked polyacrylate used as the second PSA in the patent examples."
    • D12 is "DURO-TAK and GELVA Transdermal Pressure Sensitive Adhesives - Product Selection Guide, Henkel,"
    • Whether the skilled person could make "Duro-Tak 87-2051" was not relevant to the decision, entirely in line with G 1/23. 
  • "Consequently, the skilled person willing to provide an alternative TTS to the one in Example 1 of D1 would arrive at the subject-matter of claim 1 of auxiliary request 3 in an obvious manner in view of D12."
EPO 
The link to the decision can be found after the jump.

04 October 2024

T 0606/22 - Factory visit as (no) public prior use

Key points

  • The alleged public prior use is a visit of a person to a plant.
  • The Board, in machine translation: "In the present case, all evidence relating to the alleged obvious prior use was within the sphere of influence of the [former] opponent, who relied on a video made during a visit by one of its employees, the witness Mr. Traum, to Sante A. Kowalski Sp.j. The obviousness of the prior use therefore had to be proven without gaps by the opponent"
    • The opponent had withdrawn the opposition in appeal before the summons. The proprietor and the opponent had both appealed the decision to maintain the patent in amended form. 
  • "The opposition division based its finding on the obviousness of the prior use on the testimony of the witness Mr. Traum. In his testimony, the witness stated that during the visit to the Sante A. Kowalski Sp.j. premises on which the prior use was based, he was under no obligation with regard to what he had seen in the premises (see the minutes of the taking of evidence, page 2, last full paragraph). He further stated that he was not prevented from taking video recordings on the premises. He stated that he could not remember any instructions regarding confidentiality (see ibid., page 5, paragraphs 2 and 3). In addition, the witness stated that he had to sign at the access control to comply with hygiene and safety regulations (see ibid., page 2, paragraph 5)."
  • "In its written submission of 3 June 2022, the patent proprietor submitted, through document A38, two versions of a "Guest Statement" from Sante A. Kowalski Sp.j., which are essentially identical with regard to points 3 and 9 on confidentiality, and which it claims had to be signed by every visitor to the premises of Sante A. Kowalski Sp.j. during the relevant period of the alleged prior public use.
  • "2.5 Both "Guest Statements" appear to be consistent with the witness's statement regarding the access control in place during his visit to Sante A. Kowalski Sp.j. and the obligation of visitors to sign a declaration.
  • 2.6 However, contrary to the vague statement of the witness, document A38 contains explicit provisions on confidentiality and a prohibition on video recordings on the premises without the consent of Sante A. Kowalski Sp.j. 
  • "the submission of document A38 raises considerable doubts about the opposition division's finding that Sante A. Kowalski Sp.j. had no interest in confidentiality. Rather, confidentiality for visitors appears to have been standard practice. It is not apparent that an exception was made for certain groups of visitors, such as service technicians. The witness also only mentions access control in general terms.

    2.8 These doubts can no longer be verified in the present proceedings, since further investigations to clarify the facts necessarily require the cooperation of the opponent, given its influence over the evidence, who has, however, withdrawn its opposition. The board therefore concludes that, following the submission of document A38, there are sufficiently justified doubts as to the obviousness of the prior use (see T 1534/16, in particular point 1 of the reasons). "

  • The opponent had withdrawn the opposition in 2024.

  • The Board considers the public prior use to be not proven. 

  • :" In its preliminary opinion of 2 August 2019 and 23 June 2020, the opposition division came to the preliminary view that, with the exception of the asserted obvious prior use, all objections raised up to that point in time were unlikely to be successful under the ground of opposition under Article 100(a) EPC. The novelty objection based on D15 was not admitted into the proceedings due to a lack of prima facie relevance. With regard to the objections newly filed with the written submissions in the appeal proceedings, in particular public prior use IV, the board sees no reason why these should be admitted into the proceedings.

    The Board therefore sees no reason to remit the case to the Opposition Division for continuation of the opposition proceedings under Rule 84(2) EPC.

    4. Accordingly, there are no grounds for opposition under Article 100 EPC which would manifestly preclude the maintenance of the patent in its granted form. "

  • The patent is maintained as granted.

EPO 
The link to the decision and an extract of it can be found after the jump.

28 August 2024

T 2149/21 - Commerical products as prior art

Key points

  •  "The appellant [opponent] submits that the method of operative claim 1 lacks novelty over the polymerization method described in document D32 [Comar Chemicals (Pty) Ltd, Quality Operational Procedure, Polymerization of Butadiene with Neodymium Finished catalyst] when using the catalysts under the trade names COMCAT Nd-FC (NH), COMCAT Nd-FC/20 (NH) and COMCAT Nd-FC/SF of COMAR CHEMICALS (Pty) Ltd, whose commercial availability at the relevant date of the patent in suit is mentioned in paragraph [0075] of the patent in suit and in the priority documents."
  • "Document D32 was allegedly conjointly delivered to customers of said catalysts. Accordingly, the prior use invoked by the appellant concerns the use of the catalysts under the trade names COMCAT Nd-FC (NH), COMCAT Nd-FC/20 (NH) and COMCAT Nd-FC/SF of COMAR CHEMICALS (Pty) Ltd in the method described in D32."
    • Note, the Board does not speak of 'public prior use'. Probably, the actual use of the catalyst by the buyers inside their chemical plants was not public. 
  • "The opposition division was of the opinion that the subject matter of claim 1 was novel over the alleged prior use. The only reason provided concerns steps (i), (ii) and (iii), none of which is in the opposition division's opinion unambiguously disclosed in D32"
  • "The opposition division, however, only took position on what document D32 would describe, but not on all elements alleged to be constitutive of the prior use invoked. Whereas it seems that the appellant's submissions concerning step (iii), i.e. the way to add the alkylating agent are only based on D32, the appellant's submissions concerning steps (i) and (ii) relied on other documents, in particular documents D20 to D23 and D31, as well as information provided in paragraph [0075] of the specification. Those submissions were not analysed in the contested decision. "
    • I think the case is about inherent features as anticipating, but the Board's decision is not explicit about that.
  • "Concerning step (ii), it is the position of the appellant in view of point 6 of declaration D31 that due to storage and shipment the catalysts mentioned in paragraph [0075] are necessarily aged for more than 5 days. This argument was not dealt with in the contested decision, although this was not only addressed in D31, but stressed in the notice of opposition"
  • "The appellant's submissions concerning the public availability of COMCAT Nd-FC (NH), COMCAT Nd-FC/20 (NH) and COMCAT Nd-FC/SF of COMAR CHEMICALS (Pty), [which are undisputedly catalyst according to step (i) of claim 1] which was addressed in point 5.2 of the notice of opposition, were not dealt with in the reasons for the contested decision. The opposition division only considered document D32, but not all submissions and evidence relative to the alleged prior use, namely the sale and delivery of these catalysts to which a document D32 describing their use in a polymerization procedure was allegedly attached.  
  •  "the failure of the opposition division to give due consideration to facts, evidence and arguments, which from the appellant's submissions are central to the alleged lack of novelty of claim 1 over the invoked prior use, constitutes a violation of the right to be heard in contravention of Article 113(1) EPC."

  • We will have to see if G 1/23 (not yet available at the time of writing) has any relevance for this case. 
EPO 
The link to the decision and an extract of it can be found after the jump.

03 June 2024

T 0694/19 - Sale of the factory as prior art (?)

Key points

  • The OD rejects the opposition. The opponent/appellant argues as follows: "The BAOCAL plant had been made available to the public by means of a sale. The respondent [proprietor] was the customer [buyer] having bought and received the BAOCAL plant from the legal predecessor of the appellant [opponent and was thus in a position to provide evidence on any non-disclosure agreement which might have prevented the public disclosure of the prior use BAOCAL. In the absence of this evidence, it had to be concluded that the prior use BAOCAL was rendered public by its sale to the respondent [proprietor]."
  • The Board buys the argument. "According to well-established case law, a single sale is sufficient to render the article sold available to the public within the meaning of Article 54(2) EPC, provided that the buyer was not bound by an obligation to maintain secrecy, even if it is not proved that others also had knowledge of the relevant item (see Case Law of the Boards of Appeal, 10th edition, I.C.3.3.1). If the contracting parties had wanted to exclude the sale and delivery from public accessibility, they would have had to agree on a secrecy obligation."
  • "In the present case, it was not shown that the parties to the contract were bound by any obligation to maintain secrecy. In particular, the respondent has not alleged, and there is no evidence on file, that the sales contract[]  comprised a non-disclosure agreement between the parties to the contract. In this context it is observed that the agreement terminating the above-mentioned contract (D1E) does not mention any obligation to keep the particulars of the BAOCAL plant secret in the future either - while several regulations and further obligations of the parties were agreed upon - after the contract had been explicitly terminated in 1993."
  • "Consequently, the acts of selling and delivering the plant rendered it available to the public. The mere assertion of the respondent that a production hall within which the calcining system is usually located is not open to the public is not sufficient to cast doubt on the public availability of the system sold from one company to the other. The fact that the respondent later decided to file a patent application cannot have an impact on whether or not the system was made public by the sale.
    Consequently, in view of the available evidence, it must be concluded that the BAOCAL plant was made publicly available before the priority date and thus forms part of the prior art according to Article 54(2) EPC."
  • Preliminary, I think a distinction can be made between the sale of a physical object as such and a business unit. A business unit includes both the tangible assets, the employees, and the IP, including the knowledge of how to operate the plant (with the note that in the absence of any contractual clause, both the seller and the buyer of a business unit would possess such trade secrets). Just as the way that the fact that inventor is free to talk about the invention constitutes no disclosure before he does so, the same principle could apply in the case of the sale of business units. 
    • A different situation would be if plant equipment is sold (there is a company selling "second hand" chemical plants on a website, but that refers to a set of equipment, not to up-and-running plants, as I understand it). 
  • Note, however, that the Board considers claim 1 to be inventive over the public prior use, so the analysis about the public availability of the plant is, strictly speaking, obiter.
  • Comments are welcome!


EPO 
The link to the decision is provided after the jump, as well as (an extract of) the decision text.

06 May 2024

T 1324/21 - Spontaneously forming polymorphs

Key points


  • From Derk Lowe's weblog: "The classic story is ritonavir, the anti-HIV medication (now used as a CYP metabolism inhibitor in Paxlovid and other formulations). Eighteen months after FDA approval and the arrival of the drug on the market, a more stable and less soluble polymorph began to take over the world, first noticed as a higher dissolution-test failure rate on the manufacturing line. This extremely unwelcome development precipitated a crisis (couldn’t resist the wording) which was only solved by a great deal of experimentation under severe time pressure, and the whole affair greatly impacted severely ill patients while costing Abbott hundreds of millions of dollars." (https://www.science.org/content/blog-post/stalking-polymorphs) 
  • See here for a further review, also discussing patent litigation on polymorphs: https://onlinelibrary.wiley.com/doi/full/10.1002/anie.201410356
  • Turning to the present case, claim 1 is directed to a pharmaceutical composition comprising rifaximin in polymorphic form alpha and in polymorphic form delta, and comprising 10 wt% to 45 wt% filler.
  • The OD found the claim to be novel, as follows: " Xifaxan tablets of batch 13012, which according to document D9 were purchased before the priority date, had been shown in document D7 to comprise the polymorph forms alpha and delta of rifaximin in the ratio and total amount as defined in claim 1 of the main request. However, it had not been demonstrated that these Xifaxan tablets could be analysed to comprise a relevant amount of filler." 
  •  The proprietor argued as follows for inventive step: " The Xifaxan tablets of batch 13012 comprised in addition to rifaximin form alpha also rifaximin form delta. The presence of rifaximin form delta was contrary to the official documentation on the Xifaxan tablets, in particular document D15, according to which only rifaximin form alpha was used for the preparation of the tablets, which would not convert to other forms during manufacture or storage. Document D15 actually recommended to ensure that the commercial preparation of rifaximin is the poorly absorbed polymorphic form alpha in view of the greater oral bioavailability of other polymorphic forms. The Xifaxan tablets of batch 13012 were therefore defective and unsuitable as starting point for the assessment of inventive step." 
  • The Board, on novelty: " The declaration in document D44 reports that Xifaxan 550 mg tablets as available on the market before the priority date of the patent had been prepared using the filler MCC with a water content of 3.2% in an amount which corresponded to 29.9 wt% of filler in the tablets [] Document D44 therefore indicates that the Xifaxan tablets of batch 13012 did indeed comprise an amount of filler as defined in claim 1 of the main request." 
  • " The experimental report in document A55 demonstrates that the amount of filler in Xifaxan tablets of batch 13012 could be analysed using methods as described in documents A56 and A57, which were available at the relevant time. Document A55 confirms that using these methods the Xifaxan tablets of batch 13012 were found to comprise a MCC content of 28.2-29.0% on the basis of dry MCC " 
  • " Accordingly, the Board concludes that the subject-matter of claim 1 of the main request lacks novelty." 
  • Auxiliary Request 1 is limited to a method of preparing a tablet comprising " providing (A) rifaximin in polymorphic form alpha and (D) rifaximin in polymorphic form delta"  and compressing.
  • The question is whether the public prior use is a suitable starting point for inventive step. " Whilst the originally contained rifaximin form alpha in the Xifaxan tablets of batch 13012 had thus according to document D7 apparently partially [and spontaneously, during storage] converted to form delta by 17 December 2015, these tablets had at that time not yet expired. "
  • " Contrary to the finding in the decision under appeal the Board considers that this approved market product, which had not expired, cannot be disqualified as a realistic starting point for the assessment of inventive step with respect to the method for preparing tablets comprising corresponding amounts of rifaximin form alpha and delta as defined in claim 1 of auxiliary request 1." 
  • " the Board concludes that the subject-matter of claim 1 of the auxiliary request lacks an inventive step." 
  • The patent is revoked.
  • EPO 
The link to the decision is provided after the jump, as well as (an extract of) the decision text.

01 May 2024

T 0686/22 - Does the Board play games?

Key points

  • The applicant is Nintendo.
  • "The [claimed] apparatus [i.e, the gaming device] ]is provided with a restriction process means which restricts the number of players permitted to play a multi-player game when the apparatus display means is used rather than an external TV"
  • "In its [preliminary opinion] the Board discussed for the first time the Nintendo Wii U system with its Wii U game console and Wii U GamePad operator device as prior art, in particular with reference to Nintendo customer support documentation for a Minecraft game, available on-line at the time of writing the communication. The Board will refer to this collectively as D4."
    • The Board refers to "https://en-americas-support.nintendo.com/app/answers/ detail/a_id/15831/~/how-to-start-a-multiplayer-game-%28minecraft%3A-wii-edition%29#:~:text=How%20to%20Start,mode%20will%20begin" (a page that no longer exists).
  • From the preliminary opinion:  "the appellant-applicant will undoubtably be aware of the Wii U game console (released 2012) with its Wii U gamepad. The Wii U gamepad has its own screen which can be used to display game play. It can also be connected to an external screen by HDMI cable. Therefore, it has an output destination control means. Like D1, the Wii U console also supports multiplayer games. According to the Nintendo customer support, Minecraft on the Wii U (released December 2015, thus at least a month before the relevant date of the present application) has a multiplayer split screen mode which is only supported for a [larger] HDMI external screen connected by a HDMI cable. Whist [sic] the Board realises that the above customer support information is not prior art, the Board has no reason to doubt that the Wii U playing a minecraft game would have been the same at the relevant date. " (square brackets added in the decision).
  • "The subject-matter of claim 1 differs from D4 in that, when the restriction is in place, that is when the game is played on the display means rather than the TV, multiplayer play is not performed by players exceeding a predetermined number of players. Because this claim feature is concerned with multiplayer play, it is implicit that the predetermined number of players is more than one (cf. D4's restriction to a single Minecraft player). For example, according to the invention it could be two players in accordance with the number of [two] operation devices (cf. published application, paragraph [0026])."
    • Hence, compared to D4, no longer only single player mode is available on the Wii U game pad, but also a limited multiplayer mode.
  • The Board considers the feature to be not inventive.
  • "the idea of restricting the number of players permitted to play a certain game according to the screen used (display or TV) determines how gameplay is permitted to develop and thus lies firmly in the domain of the game designer who conceives the game. The game designer will make this choice based, amongst other things on the screen area and screen resolution needed for a player to comfortably view the content of a particular game. Moreover, the players will be well aware of the game designer's choice in this respect: They would know that using a certain screen determines how many players can play the game. Thus the Board considers that a game rule underpins this feature."
  • "the Board adopts the approach as set out in T 1543/06 (Gameaccount) which is based foremost on T 0641/00 (Comvik, OJ EPO 2003, 352). Thus, only those features that contribute to technical character are to be taken into account when assessing inventive step. That requirement cannot rely on excluded (non-technical) subject-matter alone, however original it may be. The mere technical implementation of something excluded [under Art. 52(2), i.e. a game rule] cannot therefore form the basis for inventive step. Rather, it is necessary to consider in detail how that matter has been technically implemented."

EPO 
The link to the decision is provided after the jump, as well as (an extract of) the decision text.

15 April 2024

T 0273/23 - Purpose of the method

Key points

  • The decision in this appeal against a refusal was taken rather fast: statement of grounds filed 08.02.2023 (by a professional representative), oral proceedings held 27.10.2023. The applicant is a natural person (and a patent attorney).
  • Claim 1 in machine translation: "Method for positioning an art object (1) on a flowing body of water, wherein the art object (1) comprises two or more buoyant elements (3, 3 '), and at least one of the elements (3) is anchored at a position defined in the direction of flow and the other elements (3') are either also anchored or connected to one element (3)."
  • The applicant argues that claim 1 is novel over D5 because in D5, the art object is positioned in a bay, which is not a flowing body of water. 
  • Of note (in machine translation): "The CNN report (D5) on the artistic work "SOS (Safety Orange Swimmers)", which has been freely available to the public on the Internet since October 13, 2016, undisputedly constitutes prior art in accordance with Article 54(2) EPC represents. This report was introduced into the appeal proceedings by the Chamber with the notification pursuant to Article 15(1) RPBA dated April 12, 2023.
  • The Board: "The claimed method according to claim 1 mentions positioning in flowing water only as part of a purpose of the method ("for positioning an art object on a flowing body of water"). The procedure is therefore not limited further than by the suitability in this regard. It is therefore anticipated by any other positioning method of an art object, which is inherently suitable for being used for positioning in or on a river."
    • Compare Guidelines, F-IV, 4.13: "Where the stated purpose defines the specific application of the method, this purpose requires additional steps which are not implied by or inherent in the other remaining steps defined in the claim, and without which the claimed process would not achieve the stated purpose. Hence a method claim that defines a working method which, for example, commences with such words as "Method for remelting galvanic layers", the part "for remelting ..." is not to be understood as meaning that the process is merely suitable for remelting galvanic layers, but rather as a functional feature concerning the remelting of galvanic layers and, hence, defining one of the method steps of the claimed working method (see T 1931/14 and T 848/93)."
    • "On the other hand, where the purpose merely states a technical effect which inevitably arises when carrying out the other remaining steps of the claimed method and is thus inherent in those steps, this technical effect has no limiting effect on the subject-matter of the claim. For example, a method claim concerning the application of a particular surface active agent to a specified absorbent product and defining its purpose as "for reducing malodor" in terms of an intended technical effect is anticipated by a prior-art document describing a method having such suitability "for reducing malodor" although not mentioning the specific use"
    • The Board cites T 1931/14 and reasons, in machine translation: "a purpose (here the positioning of an object in a flowing body of water) does not have a restrictive effect if this effect inevitably arises when exercised of the remaining steps of the claimed method. However, anchoring an object ultimately always leads to a fixed position of this object, so that no further (implicit) features are associated with the anchoring beyond the positioning of the object."
    • The claim is held to be not novel.
    • As a comment, it's not clear to me why the method is not considered to involve an implicit step of placing the art object in a flowing body of water. 
EPO 
The link to the decision is provided after the jump, as well as (an extract of) the decision text.

  


20 March 2024

T 1416/21 - Reworking the example from 1956

Key points

  • The claim at issue is a product claim directed to " "Crystalline 2'-O-fucosyllactose polymorph II" (having certain XRD peaks) . The compound 2'-O-fucosyllactose  "was first discovered in the 1950s in human milk" (wiki)
  • D1 is Kuhn, R. et al., Chem. Ber. 1956, page 2513
  • The opponent/respondent: "  Method 2 of D1 represented an enabling disclosure. Experiment 1 of D21 was a proper repeat of method 2 of D1, i.e. a repeat which the skilled person would have carried out having their common general knowledge in mind. The product of experiment 1 of D21 showed the XRPD peaks provided for in claim 1 of the main request and auxiliary requests 1 to 9. "
  • " The board agrees with the respondent that experiment 1 of D21 is a proper repeat of method 2 of D1, i.e. a repeat which the skilled person would have carried out having their common general knowledge in mind. In particular, in both method 2 of D1 and experiment 1 of D21, amorphous 2'-FL is dissolved in a certain volume of aqueous methanol and the solution is diluted with the same volume of n-butanol. Afterwards, a few drops of n-hexanol are added and crystallisation is carried out at 4 °C."
  • Claim 1 is found to be not novel.

EPO 
The link to the decision is provided after the jump, as well as (an extract of) the decision text.



2. The respondent put forward a novelty objection to the subject-matter of claim 1 based on D1.

3. D1 addresses the problem of providing crystalline 2'-FL. It states (lines 1 to 6) that purification of 2'-FL by repeated chromatography or via its tosylhydrazone does not immediately yield crystalline 2'-FL. Rather, a syrup or, after treatment with alcohol, an amorphous white powder is obtained first.

3.1 According to D1 (lines 6 to 10), crystalline 2'-FL can be obtained from the above-mentioned syrupy 2'-FL as follows (denoted as "method 1" by the parties):

"Nach längerem Aufbewahren von 2.1 g eines mit Wasser abgedampften Sirups bei ~20° schieden sich am oberen Teil der Kolbenwand einige weiße Kriställchen ab, mit deren Hilfe sich der gesamte Sirup über Nacht in ein lockeres Kristallpulver verwandeln ließ."

[translation by the board: After storing 2.1 g of a water-evaporated syrup for an extended period of time at approximately 20°, some white crystals separated at the upper part of the wall of the flask, with the help of which the entire syrup could be transformed into a loose crystalline powder overnight.]

3.2 D1 further discloses (lines 10 to 17) that, starting from amorphous 2'-FL, crystalline 2'-FL can be obtained as follows (denoted as "method 2" by the parties):

"Ein anderer Ansatz, in dem nach mehrwöchigem Aufbewahren bei +4° spontan Kristallisation eintrat, war durch Lösen von amorphem Trisaccharid in wasserhaltigem Methanol und Zugabe des gleichen Volumens n-Butanol sowie einiger Tropfen n-Hexylalkohol bereitet."

[translation by the board: Another approach, in which spontaneous crystallisation occurred after several weeks of storage at +4°, was conducted by dissolving amorphous trisaccharide in aqueous methanol and adding an equal volume of n-butanol along with a few drops of n-hexyl alcohol.]

3.3 Finally, D1 states (lines 19 to 22) that crystalline 2'-FL can also be obtained by using the crystalline products of the above two methods as seed crystals in the following method (denoted as "method 3" by the parties):

"Besitzt man Impfkristalle, so läßt sich die Fucosido-lactose (l g) durch Lösen in heißem 75-proz. Methanol (20 ccm) und allmähliche Zugabe von absol. Äthanol (60-80 ccm) leicht in schönen dreieckigen Plättchen (Abbild.) vom Schmp. 230-231° (Zers.) erhalten."

[translation by the board: If seed crystals are available, fucosido-lactose (1 g) can be easily obtained as nice triangular plates (see image) with a melting point of 230-231° (decomposition) by dissolving the crystals in hot 75% methanol (20 ccm) and gradually adding absolute ethanol (60-80 ccm).]

3.4 The above understanding of D1, i.e. that method 3 uses the crystals of method 1 or 2 as seeds, is consistent with the summary of D1 in paragraph [0003] of the patent and was also common ground between the parties at the oral proceedings before the board.

3.5 With respect to the crystalline 2'-FL obtained, D1 also states (lines 22 to 23) that it is non-hygroscopic.

This property of the crystalline 2'-FL is mentioned in D1 only after the description of method 3. Contrary to the appellant's view, however, this does not mean that this property characterises only the crystals resulting directly from method 3. In the present case, the crystals obtained by method 1 or 2 are used as seed crystals in method 3 (see above). This means that the crystals of method 3 are obtained from these seed crystals by further growth. Therefore, the board concurs with the respondent that it is not apparent why the crystals from method 3 should have different properties than those resulting from method 1 or 2. In summary, D1 can only be understood as meaning that the above property (non-hygroscopic) characterises the crystals of 2'-FL no matter which of the three disclosed methods is used.

4. D1 does not disclose XRPD reflections of the crystals from any method or the degree of their purity in w/w%. However, this does not mean that its disclosure cannot be novelty-destroying. To the extent that the teaching of D1 is sufficient for the skilled person, in light of their common general knowledge, to obtain the product of claim 1 (in other words: if D1 provides an enabling disclosure for the product of claim 1), D1 would be novelty-destroying to claim 1.

4.1 In this context, experiment 1 of D21 (page 2/20) is relevant. It reads as follows (text in square brackets added by the board):

"In order to repeat the Method 2 in Literature 1 [D1] the following experiment was carried out: 2.527 g of amorphous 2-FL [2'-FL] was dissolved in 100 ml of aqueous methanol (99 ml of anhydrous methanol + 1 ml of water), and the white solids were gradually dissolved under continuous stirring, the liquid became a white turbid liquid, and then 100 ml of n-butanol was added, and more white solids were precipitated. The solution was filtered to obtain a colorless transparent solution, and then 400 myl of n-hexanol was added to the filtrate, and shaken. The solution was transferred to a 250 ml conical flask, sealed with a parafilm perforated with several small holes, and stored at 4 °C for 2 weeks. The crystalline product was filtered, washed with methanol, and dried in vacuo to obtain 0.314 g of white crystals."

4.2 The board agrees with the respondent that experiment 1 of D21 is a proper repeat of method 2 of D1, i.e. a repeat which the skilled person would have carried out having their common general knowledge in mind. In particular, in both method 2 of D1 and experiment 1 of D21, amorphous 2'-FL is dissolved in a certain volume of aqueous methanol and the solution is diluted with the same volume of n-butanol. Afterwards, a few drops of n-hexanol are added and crystallisation is carried out at 4 °C.

4.3 As is evident from figure 4 and table 1 of D21 (pages 10/20 and 11/20), the crystals obtained from this repeat show the XRPD reflections recited in claim 1. This was also never disputed by the appellant.

4.4 Furthermore, as already set out above, D1 uses a 2'-FL as the starting material for its crystallisations which had previously been purified by repeated chromatography or via its tosylhydrazone. D1 (last sentence) also states that no other sugars could be detected in the mother liquors by paper chromatography after crystallisation.

Against this background, at least in the absence of any evidence to the contrary, which the appellant did not provide, the board is convinced that the crystalline 2'-FL obtained according to the disclosure of D1 and in particular method 2 does not contain any impurities.

5. The appellant submitted that D1 did not disclose method 2 in an enabling manner. In this respect, it referred to paragraph [0016] of the patent, stating that the inventors of the patent had never been able to reproduce the methods described in D1. Decisions T 325/16 and T 605/02 were relevant in this context. In particular, the appellant argued that several pieces of information were lacking in D1 so that especially method 2 might not be reproduced. Experiment 1 of D21 filled in these gaps in the disclosure of method 2 of D1. Contrary to D21, D1 did not specify the amounts of solvents or 2'-FL used nor did it exactly specify the number of drops of n-hexanol added or the storage time; moreover, D21 disclosed that the liquid became a white turbid liquid, an item of information that was not mentioned in D1. Therefore, several additional assumptions had been made in D21 that could not be derived from D1 nor from the skilled person's common general knowledge. The appellant also pointed to the fact that, according to D21, the crystalline product was obtained after only two weeks, whereas D1 disclosed the obtention of the crystals after "several weeks".

Furthermore, the appellant referred to D6 and submitted that it was evident from figure 1 of D6 (page 946) that several parameters such as e.g. choice of solvent, temperature, concentration, agitation and pH all had an effect on the type of polymorphic form that was obtained from a solution during crystallisation. Therefore, it was entirely conceivable that the polymorph as defined in claim 1 had been obtained in D21 by selecting appropriate operating conditions that were not mentioned in D1 but that only slight changes in the crystallisation conditions of experiment 1 of D21 would have resulted in a different polymorph.

Hence, the appellant argued that D21 was not a proper repeat of method 2 of D1 and therefore it could not be concluded that the 2'-FL polymorph of claim 1 was necessarily obtained when following the teaching of method 2 of D1.

6. The board is not convinced by these arguments for the following reasons.

6.1 It is clear that method 2 of D1 is not described to the very last detail. However, this does not allow the conclusion that the method is necessarily not disclosed in an enabling manner. In the present case, the board is convinced that the skilled person, having their common general knowledge in mind, would have known how to put method 2 of D1 into practice. The appellant's arguments are not suitable for casting doubt on this for the following reasons.

6.1.1 First of all, both the storage time at 4 °C (2 weeks) and the amount of n-hexanol (400 myL, i.e. about 8 drops) reported in D21 are fully in line with the disclosure of method 2 in D1 ("nach mehrwöchigem Aufbewahren" [translation by the board: after several weeks of storage], "sowie einiger Tropfen n-Hexylalkohol" [translation by the board: along with a few drops of n-hexyl alcohol]). In the absence of evidence to the contrary, which the appellant did not put forward, the board sees no reason to doubt that the skilled person would very well have chosen the storage time and number of drops of n-hexanol as stated in experiment 1 of D21.

6.1.2 Secondly, it is true that the amounts of solvents and 2'-FL used in experiment 1 of D21 are not disclosed in D1. However, the skilled person is well aware that any compound which is to be crystallised from a solvent or a solvent system has a certain solubility at a certain temperature in said solvent (system). Consequently, depending on the amount of compound to be crystallised, the skilled person would have used only those amounts of solvent(s) which result in a concentration of the compound to be crystallised which is above the solubility limit at the crystallisation temperature, because no crystallisation at all could otherwise have been achieved. In simpler terms, as argued by the respondent, the skilled person would have known how much solvent to use depending on the amount of 2'-FL to be crystallised. This is what has been done in experiment 1 of D21.

6.1.3 Thirdly, D21 also states that "the liquid became a white turbid liquid" upon dissolution of the amorphous 2'-FL in aqueous methanol. The appellant pointed to the fact that this observation is not described in method 2 of D1. This argument implies that according to the appellant, the solution in D1 must have been clear upon dissolution of the amorphous 2'-FL in aqueous methanol. However, in the absence of evidence to the contrary, which the appellant did not provide, the board sees no reason for this assumption. In fact, according to experiment 1 of D21 (loc. cit.), a clear solution is obtained by filtration. Thus, the board is satisfied that this is exactly what the skilled person would have done by following method 2 of D1 if they had wanted to prepare a solution from which a compound was to be crystallised.

6.2 Therefore, the appellant's arguments cannot change the conclusion above that method 2 of D1 is disclosed in an enabling manner and that experiment 1 of D21 is a proper repeat of method 2 of D1, i.e. a repeat which the skilled person would have carried out having their common general knowledge in mind.

6.3 In view of the above, the mere assertion in the patent that the appellant tried in vain to repeat the methods of D1 is not convincing. In fact, as submitted by the respondent, the appellant has not provided any details concerning the operating conditions that might have been used in these attempts to reproduce the methods of D1 and which would not have allowed crystallised 2'-FL to be obtained.

6.4 It may be that, as argued by the appellant with reference to D6, a slight modification of the crystallisation conditions of experiment 1 of D21 could have in principle resulted in a different polymorph. However, the allegation that such is exactly the case here has never been proven by the appellant and, thus, amounts to mere speculation.

6.5 The appellant also referred to decisions T 325/16 and T 605/02, arguing that a polymorph disclosed in the prior art in a non-enabling manner could not be novelty-destroying. The board had already pointed out the lack of relevance of these decisions in its communication pursuant to Article 15(1) RPBA 2020 (see point 3.4.8). This is because the underlying facts were different from the facts at hand. Moreover, as set out above, the board is convinced that the polymorph defined in claim 1 is disclosed in D1 in an enabling manner. At the oral proceedings before the board, the appellant no longer relied on these decisions in its argumentation. Hence, the board sees no reason to comment on them further.

7. Therefore, the board concludes that method 2 of D1 is disclosed in an enabling manner and that it results in the claimed 2'-FL polymorph without any impurities. Hence, the subject-matter of claim 1 of auxiliary request 2 is not novel over D1. Auxiliary request 2 is not allowable.

Main request and auxiliary request 1 - Claim 1 - Novelty (Article 54 EPC)

8. Claim 1 of auxiliary request 1 differs from claim 1 of auxiliary request 2 only in that it allows for a higher degree of impurity ("less than 10 w/w% of impurity" in claim 1 of auxiliary request 1 vs. "less than 5 w/w% of impurity" in claim 1 of auxiliary request 2). Claim 1 of the main request (claim 1 as granted) does not set any limit to the amount of impurity.

Therefore, the subject-matter of claim 1 of auxiliary request 2 is fully encompassed by the subject-matter of claim 1 of the main request and auxiliary request 1. The above reasoning of lack of novelty for the subject-matter of claim 1 of auxiliary request 2 therefore also applies to the subject-matter of claim 1 of the main request and auxiliary request 1.

It follows that the subject-matter of claim 1 of these requests is not novel over D1 and therefore the main request and auxiliary request 1 are not allowable.


23 October 2023

T 1996/20 - A blog post as prior art

Key points

  • In what has a distinct EQE Paper C vibe: "Document D4 is a disclosure made available on the internet in the form of a blog entry published at a certain date followed by a series of user comments posted at a later point in time. In the present case, the board has no doubt that the content of the blog entry dated 15 June 2013 ("2013 06/15") as well as the first three comments on page 6/7 of 16 June 2013 and 10 October 2013 were made available to the public before the priority date of the patent in suit, i.e. before 29 January 2014. With the exclusion of the last five comments of pages 6/7 and 7/7, posted between 3 December 2014 and 16 March 2016, document D4 therefore constitutes prior art under Article 54(2) EPC." 
    • " D4 - "Lexan: The 3D-Printer build platform of the future", dated between 15 June 2013 and 16 March 2016, retrieved from the internet (http://www.akeric.com/blog/?p=2158);|" 
  • The claim is found to be obvious over the blog post in combination with a patent document D5, it seems with the teaching of a single paragraph of D5 and some dependent claims. 
    • "  In the board's view, the skilled person would not have ignored this clear and unambiguous teaching in document D5. This explicit solution to the objective technical problem would have prompted the skilled person to modify the substrate, i.e. the flexible Lexan sheet, of document D4 by texturing its top surface. In so doing, the skilled person would have arrived at the subject-matter of claim 1 of the patent as granted. Hence, the claimed subject-matter is obvious." 

  • The rest of the decision is also interesting, including a discussion of the permitted role of post-published documents under inventive step as evidence of common general knowledge, technical prejudice, "one of many feasible solutions"  and long-felt need. 
  • " The appellant's submissions concerning the "dominant thinking" and the "prejudice" at the time of filing seem to miss the point that document D4, the starting point for the inventive step assessment, already discloses an alternative to the Kapton tape, the blue painter's tape and the hairspray, namely a build plate consisting of a flat sheet of flexible material"
  • " It may very well be that the textured top surface is just one of several different feasible solutions to the objective technical problem. But it is the only solution to the problem offered by document D5."
  •   " The board does not dispute the appellant's argument that producers of 3D printers at the time the application for the patent in suit was filed relied on Kapton foil, blue painter's tape or hairspray. Documents D14 and D17 are proof thereof. However, this does not imply a long-felt need that was overcome by the claimed invention and that is therefore indicative of an inventive step." 

EPO 
The link to the decision is provided after the jump, as well as (an extract of) the text of the decision.